ArticleAdvances in hematology2025
Hematological Biomarkers in Predicting Progression and Complications of Chronic Kidney Disease Among Adult Patients.
Article in Advances in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hematological Biomarkers in Predicting Progression and Complications of Chronic Kidney Disease Among Adult Patients.Advances in hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CKD is a progressive disorder that is commonly associated with hematological abnormalities. Objective: The objective of the study was to evaluate the role of hematological biomarkers in predicting CKD progression and related complications in adult patients. Methods: The retrospective cross-sectional study evaluated hematological parameters such as hemoglobin, RBC, WBC, platelet, and NLR; comorbidities; and CKD stages were recorded for analysis. Statistical analysis methods used included ANOVA, Chi-square, multiple logistic regression, Pearson correlation analyses, and ROC curve analysis. The study was conducted under strict adherence to the principles and guidelines of the Helsinki Declaration (2013). Results: The mean age was 56.2 ± 14.8 years, with males being 56.7%. About 70.8% of the patients were in CKD Stages 3-5. Anemia was observed in 74.2% of the patients, whose prevalence increased alongside the increase in severity of CKD ( Conclusion: The performance of hematological biomarkers, mainly hemoglobin and NLR, emerges as reliable predictor of CKD progression and complications. Their assessment as part of the CKD workup may then enhance risk stratification and early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.